Eiger BioPharmaceuticals, Inc.
EIGR
Classement en actions
#36449
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Prix de l'action
$1.73
Dernière synchronisation: 2025-06-17
Capitalisation boursière
$2.55M
Changement (1 jour)
-0.29%
Changement (1 an)
-79.71%
Pays
US
Échange Eiger BioPharmaceuticals, Inc. (EIGR)
Catégorie
Healthcare
Nombre d'actions en circulation pour Eiger BioPharmaceuticals, Inc. (EIGR)
Nombre d'actions en circulation au December 2023: 1.48M
Selon les derniers rapports financiers et le cours de l'action de Eiger BioPharmaceuticals, Inc., le nombre actuel d'actions en circulation est de 1.48M. À la fin de December 2022, l'entreprise avait 1.39M actions en circulation. Le nombre d'actions en circulation est généralement affecté par les divisions d'actions et les rachats d'actions.
Historique des actions en circulation de Eiger BioPharmaceuticals, Inc. (EIGR) de 2016 à 2026
Actions en circulation à la fin de chaque année
| Année | Actions en circulation | Changez |
|---|---|---|
| 2026 (TTM) | 1.48M | 0.22% |
| 2023 | 1.48M | 6.39% |
| 2022 | 1.39M | 22.64% |
| 2021 | 1.13M | 20.61% |
| 2020 | 938.11K | 23.51% |
| 2019 | 759.52K | 66.18% |
| 2018 | 457.03K | 57.09% |
| 2017 | 290.93K | 45.30% |
| 2016 | 200.23K | 0.00% |
Actions en circulation pour des entreprises similaires ou concurrentes
| Entreprise | Actions en circulation | Différence | Pays |
|---|---|---|---|
| 253.90M | 17,061.24% |
US
|
|
| 396.00M | 26,665.85% |
US
|
|
| 478.91M | 32,269.92% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | 4,103.15% |
NL
|
